Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer

AstraZeneca

Status: Completed

Conditions: Advanced Breast Cancer

Treatments: Drug: anastrozole

Study type: Observational

Funder types: Industry

Identifiers

NCT00562458

NIS-ARO-HCH-2006/1

Details and patient eligibility

About

To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.

Enrollment: 200 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients to be included in the program are that ones according to the indications specified in the Romanian anastrozole (Arimidex) approved SmPC (attached to the protocol)and who are already treated with anastrozole for at least 1 month before inclusion in this program/non-interventional study.

Exclusion criteria

• Patients not to be included in the programme: patients who have a known hypersensitivity to anastrozole (Arimidex®) or any of its excipients.